Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Quick Summary

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Nov 11, 2021 11:39am

142 Views

Post# 34115157

RE:Quick Summary

"if less than 1or more with DLT they increase.."
if more than one or more!

scarlet1967 wrote:

Oncology:

As per new dose escalation slide they dosed first patient with 30mg/m2 second patient 2x30mg/m2=60mg/m2 third patient 2x60mg/m2=120mg/m2 forth patient 1.67x120mg/m2=200mg/m2 fifths patient 200mg/m2x1.5=300mg/m2 and last single and sixth patient 300mg/m2x1.4=420mg/m2, it seems they have started dosing group of 3 patients at 420mg/m2 if no DLT planning to increase the dosage by factor of 1.33(420mg/m2x1.33)560mg/m2 on next group of 3 if DLT they dose a group of 6 if less than 1or more with DLT they increase the dosage by factor of 1.33 again in next group of 6 patients until 1 or more patient shows DLT. He confirmed even at twice the level of Docetaxel their intracellular concentration of anti-cancer agent could be multiples of Docetaxel alone theoretically up to 8 time more.

It looks like the amount of Docetaxel released in blood stream in humans is similar to animals based are incoming data which they haven’t published but are monitoring. Paul mentioned they will be starting the combination therapy (TH19 series+ immunotherapy) possibilities in clinic. Their peptide can potentially conjugate to SN-38 a very potent cytotoxic agent and small interfering RNA (molecule which can regulate and effect the expression of genes) in order to silence the protein responsible for cancer cells growth.

NASH:

They are having conversations with few potential partners failing that they want to fund the trial in a responsible manner without effecting the investors negatively.

They have a commercial business which can be used as a collateral in order to raise funds. Also they will be finding the trial in in installments ”chops of payments” so there is no need to raise huge amount of funds initially.

Legacy drugs:

They are optimistic on Tesamorelin as it seems both passed sales and incoming prescription are rising and Trogarzo (long lasting drug) which “seems to be more relevant now” will be launched in multiple European countries once the pricing is confirmed